Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the real-world effectiveness of nemolizumab Nemluvio4 in treating adults with moderate-to-severe Prurigo Nodularis PN. This observational study aims to measure patient and investigator-reported outcomes over approximately 12 months in routine clinical practice. The study focuses on how patients respond to nemolizumab treatment at 6 months, with ongoing assessments up to a year. Participants who have newly started nemolizumab as determined by their physicians will be observed during their usual care visits. No extra visits, procedures, or lab tests beyond routine care are required. A sub-study in Germany and the UK involves daily patient-reported ratings of itch severity and sleep disturbance for two weeks, collected remotely without clinic visits. During the study, participants will undergo routine evaluations by their doctors, including the Investigator Global Assessment of chronic prurigo stage and questionnaires on itch intensity and sleep quality. These assessments occur at 6 months and continue up to 12 months. This approach allows tracking of treatment effects in real-life settings while minimizing additional burden on participants.
Actively Recruiting
Researchers are evaluating the real-world use of nemolizumab for treating moderate-to-severe atopic dermatitis AD in adolescents and adults. This observational study aims to assess the treatments effectiveness through physician evaluations and patient-reported outcomes over six months, providing insight into how the medication performs in everyday clinical practice. Participants receiving nemolizumab as part of their routine care will be observed for about 12 months. Treatment decisions are made by the participants physician before joining the study, with no extra visits or tests beyond usual medical care. A sub-study in Germany and the UK involves daily remote reporting of symptoms such as peak and average itch, sleep disturbance, and pain for the first two weeks. During the study, participants will have regular medical visits as determined by their doctors, with data collected from routine assessments and patient questionnaires. Researchers will measure outcomes like the Investigator Global Assessment and Peak Pruritus Numerical Rating Scale at six months, along with other severity and symptom scores up to 12 months. No additional procedures outside standard care are required, allowing for natural monitoring of treatment effects and safety.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.
Actively Recruiting
Researchers are comparing early versus delayed treatment using venetoclax and obinutuzumab in patients newly diagnosed with high-risk chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase III trial aims to see if starting treatment before symptoms appear improves overall survival and other outcomes. Venetoclax is a BCL-2 inhibitor that may stop cancer cell growth, and obinutuzumab is a monoclonal antibody that may help the immune system attack cancer cells. Participants are randomly assigned to one of two groups one begins treatment early after meeting eligibility criteria, and the other starts treatment only after symptoms develop. Both groups receive obinutuzumab intravenously on specified days during the first six cycles and venetoclax orally daily during later cycles, with treatment repeated every 28 days for up to 12 cycles. During and after treatment, patients undergo CT scans, blood sample collections, and bone marrow biopsies. Participants are monitored for up to 10 years after treatment to assess overall survival, progression-free survival, response rates, safety, and quality of life using the FACT-Leukemia scale. Researchers collect various samples and data, including measurable residual disease status and biomarkers. Patient compliance and adverse events are also tracked to better understand the treatment effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.
Actively Recruiting
Researchers are evaluating a combination therapy for adults with newly diagnosed multiple myeloma not intended for early autologous transplantation. This phase III trial compares a four-drug regimen including daratumumab, bortezomib, lenalidomide, and dexamethasone to a three-drug regimen of daratumumab, lenalidomide, and dexamethasone. The study aims to determine if adding bortezomib improves overall survival and progression-free survival in patients with different minimal residual disease statuses, while also assessing side effects and patient-reported outcomes. All participants first receive standard induction therapy with daratumumab given subcutaneously on specific days, lenalidomide orally daily for 21 days, and dexamethasone orally on certain days, repeated every 28 days for 9 cycles. After induction, patients are randomly assigned to one of two consolidation and maintenance arms one adding bortezomib to the consolidation phase followed by maintenance with daratumumab and lenalidomide, and the other continuing with daratumumab, lenalidomide, and dexamethasone for consolidation and maintenance. Treatments continue in cycles of 28 days unless disease progresses or unacceptable side effects occur. During the study, participants undergo various assessments including bone marrow aspirates, blood tests, imaging with PETCT scans, and patient-reported quality of life evaluations. Researchers monitor overall survival, progression-free survival, response rates, adverse events, and neuropathy symptoms over periods up to 15 years. Follow-up visits occur every 3 months for up to 2 years, then less frequently, ensuring long-term monitoring of treatment effects and safety.